Should You Buy Cryo-Cell International, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Cryo-Cell International, Inc. (CCEL) carries a solid Quality of Company rating of 6.7/10. Trading at $4.38, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 5 of 8 CirclFi valuation models project upside for Cryo-Cell International, Inc. (CCEL) at $4.38 — the model consensus leans bullish, with a Quality Score of 6.7/10 and Value-Trap risk of 19/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Cryo-Cell International, Inc. (CCEL) in 2026?
What Is the Bull Case vs the Bear Case for Cryo-Cell International, Inc. (CCEL)?
| Bull case — $6.65 target (+51.9%) | Bear case — $0.20 target (-95.4%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, 5 of 8 models identify upside from $4.38 to a median fair value of $5.87, indicating the market hasn't fully priced in Cryo-Cell International, Inc.'s earnings power. | According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $0.20 (-95.4%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $6.65 (+51.9%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +147.3% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
How Does CCEL Compare to Its Medical Care Facilities Peers?
Valuation data pages: AMN · AVAH · INNV · SRTA · DCGO · SGRY · EHSI · NIVF · PACS · ADUS · NHC
Which Other Stocks Score Like CCEL on Quality?
Closest companies to CCEL’s Quality of Company score of 6.7/10, across all industries.
Which Medical Care Facilities Screens Does CCEL Appear In?
So Is Cryo-Cell International, Inc. (CCEL) Worth Buying in 2026?
The balance of evidence tilts cautiously positive for Cryo-Cell International, Inc. at $4.38. 5 of 8 models support upside to $5.87, backed by a 6.7/10 quality foundation. This is a "lean into, not load up on" setup in our framework.
These are quantitative model outputs, not investment recommendations. Cryo-Cell International, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CCEL Stock?
Should I buy CCEL stock right now?
Based on CirclFi's multi-model analysis, 5 of 8 models see upside for CCEL at $4.38. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.7/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Cryo-Cell International, Inc.?
Key risks include: wide model disagreement (3201% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Care Facilities companies. Always diversify and consult a financial advisor.
How does CCEL compare to its competitors?
Among Medical Care Facilities peers, CCEL holds a Quality Score of 6.7/10. Comparable companies include AMN (QOC 6.7), AVAH (QOC 6.7), INNV (QOC 6.8). The relative ranking helps investors identify whether CCEL offers better fundamental quality than alternatives in the same sector.
Is CCEL a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CCEL's Quality Score of 6.7/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy CCEL at?
CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $0.20 to $6.65. At $4.38, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CCEL.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad